All Clinical Trials in United Kingdom

A listing of 3097 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

United Kingdom

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Shared Decision-making and Antimicrobial Stewardship in Secondary Care

NCT06605820

Recruiting

To identify opportunities for antibiotic prescribing shared decision making between patients and prescribers in secondary care.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/29/2025

Locations: Royal Cornwall Hospital, Truro, Cornwall +1 locations

Conditions: Antibiotic Prescribing is the Study Focus (no Condition)

Learn More ›

To Perform a Post-market Study of the Performance of the Idylla ThyroidPrint Assay Using Clinical Samples in Predicting the Nature of Indeterminate Thyroid Nodules (ITNs) Across Multiple Centers.

NCT06849284

Recruiting

To perform a post-market study of the performance of the Idylla™ ThyroidPrint® Assay using clinical samples in predicting the nature of indeterminate thyroid nodules (ITNs) across multiple centers.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/29/2025

Locations: Royal Cornwall Hospital, Truro, Cornwall

Conditions: Thyroid Cancer

Learn More ›

Feasibility of Novel Clinical Trial Infrastructure, Design and Technology for Early Phase Studies in Patients With Pulmonary Hypertension (FIT-PH)

NCT04078243

Recruiting

Prospective, open-label, observational study to evaluate the safety and feasibility of using pulmonary artery pressure (PAP) monitors and wearable activity monitors in patients with pulmonary hypertension (PH).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/29/2025

Locations: Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, South Yorkshire

Conditions: Pulmonary Hypertension

Learn More ›

The Impact of OliPhenolia® Supplementation on Exercise Induced Inflammation and Functional Movement in Humans.

NCT07008586

Recruiting

This research proposal follows on from previously undertaken work investigating a commercially available olive derived product (OliPhenolia®) on potential exercise / functional benefits for healthy adults. Previous research investigated a dose response bioavailability of the main polyphenol in OliPhenolia® and related metabolites. Based on this data, the current study will aim to investigate, for the first time, whether the polyphenols in the product can positively influence exercise specific inflammation which may be pertinent to improving exercise recovery and is of current scientific interest. As such this research aims to understand the short term (Phase 1) and longer term (Phase 2) use of OliPhenolia® on acute recovery from a standard exercise bout. Research questions: 1. Does an acute dose of OliPhenolia® reduce exercise associated inflammation markers and enhance functional recovery in healthy adult humans? 2. Does a consecutive 16 day intake of OliPhenolia® reduce exercise associated inflammation markers and enhance functional recovery in healthy adult humans? 3. Does a continued intake of OliPhenolia® during the recovery period after the exercise bout further amplify functional benefits compared experimental control? Proposed methodology: Phase 1 - To answer research question 1, following a randomisation procedure, participants will be allocated product (OliPhenolia®) or colour and taste matched placebo. A single serve of product (no more than 1.5 mg/kg of hydroxytyrosol (HT) via OliPhenolia®) or placebo will be provided \~40 minutes prior to a standardised exercise protocol. Resting wholeblood samples will be collected at 0 (baseline) +1, +24, +48 and +72 hours following the exercise bout to identify the impact of an acute dose of OliPhenolia® has on selected inflammatory biomarkers. This phase will be a placebo-controlled crossover design and therefore after a ≥7 day wash out period, participants will return to the exercise laboratory (Compass House Human Physiology laboratories, Anglia Ruskin University, Cambridge), supplement the alternate product and repeat the experimental protocol as outlined above. Phase 2 - To answer research question 2, having completed Phase 1 (and following another ≥7 day wash out period), all participants will continue onto Phase 2, maintaining their previously assigned product, but this time will continue supplementation for 16 consecutive days. Phase 2 is therefore a parallel placebo-controlled design that focusses on a chronic supplementation of OliPhenolia®. Participants will consume one serve of either product or placebo twice daily for 16 days. After 16 days of supplementation participants will return to the exercise laboratory, and in the same manner as Phase 1, consume a single dose of their assigned product or placebo \~ 40 minutes prior to the standardised exercise protocol. Resting wholeblood samples will be collected following exercise at baseline, +1, +24, +48 and +72 hours. To answer research question 3, all participants will be informed that they may be asked to consume an additional three days supplementation in a random manner (total 19 days). To limit participant burden 50 % of the experimental group (those that have been supplementing OliPhenolia®) and placebo group will continue supplementing two doses daily for the three days following the standardised exercise protocol (the three days where blood samples occur) in order to understand if a sustained course of OliPhenolia® can reduce the time taken for inflammatory mediators to return to baseline values. Read Less

Gender:

ALL

Ages:

Between 21 years and 60 years

Trial Updated:

05/29/2025

Locations: Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University,, Cambridge, Not set

Conditions: Healthy

Learn More ›

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

NCT06265727

Recruiting

The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called nectin-4. The main questions it aims to answer are: What is the the safe and effective dose of CRB-701 when used alone? What cancers can be treated effectively with CRB-701? Participants will be asked to attend clinic and be given a intravenous infusion of CRB-701 on its own. They will have blood tests and other assessments to measure whethe... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/29/2025

Locations: O'Neal Comprehensive Cancer Center at University of Alabama-Birmingham, Birmingham, Alabama +43 locations

O'Neal Comprehensive Cancer Center at University of Alabama-Birmingham, Birmingham, Alabama

City of Hope Cancer Center, Duarte, California

Moores Cancer Centre at UC San Diego Health, San Diego, California

Helen Diller Family Comprehensive Cancer Center - UCSF, San Francisco, California

Rocky Mountain Cancer Centres, Denver, Colorado

Yale Cancer Center, New Haven, Connecticut

Florida Cancer Specialists, Orlando, Florida

University of Chicago, Chicago, Illinois

Hope and Healing Cancer Center, Hinsdale, Illinois

Dana-Faber Cancer Institute, Boston, Massachusetts

Nebraska Hematology Oncology, Lincoln, Nebraska

Carolina BioOncology Institute, Huntersville, North Carolina

Texas Oncology, Tyler, Texas

Virginia Cancer Specialists, Fairfax, Virginia

Fred Hutchinson Cancer Center at University of Washington, Seattle, Washington

ICM-Val d'Aurelle, Montpellier, Not set

CHU de Poitiers, Poitiers, Not set

Institut de Cancerologie de l'Ouest, St. Herblain, Not set

Gustave Roussy, Villejuif, Not set

Careggi University Hospital, Florence, Not set

European Institute of Oncology IRCCS, Milan, Not set

Fondazione Policlinico Gemelli, IRCCS, Rome, Not set

Centro Richerche Cliniche di Verona, Verona, Not set

Aresnsia Research Clinic Bucharest, Bucharest, Not set

Aresnsia Research Clinic Cluj-Napoca, Cluj-Napoca, Not set

Centrul de Oncologie Sf. Nectarie, Iaşi, Not set

Centrul de Oncologie Euroclinic, Iaşi, Not set

Barcelona IOB Hospital Quironsalud (NEXT), Barcelona, Not set

Vall d-Hebron Institut d'Oncologia, Barcelona, Not set

Fundacion Jimenez Diaz (START), Madrid, Not set

Hospital Clinico Universitario de Valencia, Valencia, Not set

Adana Numune Egitim ve Arastirma Hastanesi (Adana City Education and Research Hospital), Adana, Not set

Ankara University, Ankara, Not set

Ankara Etlik City Hospital, Ankara, Not set

Istanbul Medeniyet University, Istanbul, Not set

University of Birmingham NHS Foundation Trust, Birmingham, Not set

University of Cambridge NHS Foundation Trust, Cambridge, Not set

Velindre Cancer Centre, Cardiff, Not set

Leeds University Hospitals NHS Trust, Leeds, Not set

Guy's and St Thomas' Clinical Research Facility, London, Not set

Imperial Experimental Cancer Medicine Centre, London, Not set

The Christie Hospital, Manchester, Not set

University of Southampton, Southampton, Not set

University of Liverpool - Clatterbridge Medical Centre, Wirral, Not set

Conditions: Solid Tumor, Adult

Learn More ›

First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

NCT06603844

Recruiting

The purpose of this study is to determine the safety, blood concentrations and treatment effect of CRB-601 in combination with immunotherapy in patients who have advanced solid tumors (cancer) and have exhausted other therapeutic options.CRB-601 targets a protein called avb8 integrin which is expressed by some cancers and not others. This study will focus on tumor types which are know to highly or moderately express this protein. Researchers will evaluate the side effects caused by treatment, l... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/29/2025

Locations: University of Alabama at Birmingham, Birmingham, Alabama +25 locations

University of Alabama at Birmingham, Birmingham, Alabama

SCRI - Arizona Oncology Associates, Tucson, Arizona

The University of Arizona Cancer Center, Tucson, Arizona

UC San Diego Health - Moores Cancer Center, La Jolla, California

Cedars-Sinai Medical Center, Los Angeles, California

University of California San Francisco, San Francisco, California

SCRI - Rocky Mountain Cancer Centers, Denver, Colorado

Advent Health Oncology Hematology, Orlando, Florida

SCRI- Lake Nona DDU, Orlando, Florida

University of Chicago, Chicago, Illinois

SCRI - Minnesota Oncology Hematology, Maple Grove, Minnesota

Nebraska Hematology Oncology, Lincoln, Nebraska

Duke Cancer Center, Durham, North Carolina

University Hospital of Cleveland (Case Western), Cleveland, Ohio

SCRI - OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma

SCRI - Nashville, Nashville, Tennessee

START - San Antonio, San Antonio, Texas

SCRI- Texas Oncology, Tyler, Texas

SCRI - Virginia Cancer Specialists, Fairfax, Virginia

SCRI - Oncology and Hematology Associates of Southwest Virginia, Roanoke, Virginia

The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, Tyne and Wear

The Clatterbridge Cancer Center NHS Foundation Trust, Birkenhead, Wirral

Edinburgh Cancer Research Centre, Edinburgh, Not set

Beatson West of Scotland Cancer Center, Glasgow, Not set

Guys and St Thomas NHS Foundation Trust, London, Not set

The Christie NHS Foundation Trust - Christie Hospital, Manchester, Not set

Conditions: Solid Tumor

Learn More ›

Cooling in Mild Encephalopathy

NCT05889507

Recruiting

The goal of this randomised control trial is to establish the safety and efficacy of whole-body hypothermia for babies with mild hypoxic ischaemic encephalopathy, inform national and international guidelines, and establish uniform practice across the NHS. The main questions it aims to answer are: 1. Does whole-body cooling (33.5±0.5°C) initiated within six hours of birth and continued for 72 hours, improve cognitive development at 24 (±2) months of age after mild neonatal encephalopathy compar... Read More

Gender:

ALL

Ages:

Between 1 hour and 6 hours

Trial Updated:

05/29/2025

Locations: Neonatal Unit, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Not set +14 locations

Conditions: Neonatal Encephalopathy, Newborn Asphyxia

Learn More ›

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

NCT04996875

Recruiting

This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/29/2025

Locations: University of Alabama at Birmingham (UAB) Hospital, Birmingham, Alabama +41 locations

University of Alabama at Birmingham (UAB) Hospital, Birmingham, Alabama

Mayo Clinic Arizona, Phoenix, Arizona

City of Hope Comprehensive Cancer Center, Duarte, California

UCLA Medical Center, Los Angeles, California

Stanford Cancer Institute, Stanford, California

Galiz Research, Hialeah, Florida

Winship Cancer Institute - Emory University, Atlanta, Georgia

Rush University Medical Center, Chicago, Illinois

Dana-Farber Cancer Institute, Boston, Massachusetts

Columbia University Irving Medical Center, New York, New York

Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio

MUSC Health University Medical Center, Charleston, South Carolina

The University of Texas MD Anderson Cancer Center, Houston, Texas

Huntsman Cancer Institute - University of Utah Health, Salt Lake City, Utah

Nepean Hospital, Kingswood, New South Wales

Gold Coast University Hospital, Southport, Queensland

Peter MacCallum Cancer Centre, Melbourne N., Victoria

AKH Wien, Universitatsklinikum, Vienna, Not set

CHU de Liege, Liège, Not set

University of Alberta Hospital, Edmonton, Alberta

St. Michael's Hospital - Unity Health Toronto, Toronto, Ontario

Necker-Enfants Malades Hospital, Paris, Not set

Centre Hospitalier Universitaire (CHU) de Poitiers, Poitiers, Not set

Centre Hospitalier Universitaire (CHU) de Toulouse, Toulouse, Not set

University Hospital Aachen, Aachen, Not set

Universitätsklinikum Freiburg, Freiburg, Not set

UKSH Campus Lubeck, Lubeck, Not set

Universitätsklinikum Mannheim, Mannheim, Not set

IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Not set

Azienda Ospedaliero Universitaria Careggi, Florence, Not set

AOU San Giovanni di Dio e Ruggi dAragonia, Salerno, Not set

Azienda Ospidaleira Universitaria Integrata Verona, Verona, Not set

University Medical Center Groningen, Groningen, Not set

Oslo University Hospital, Oslo, Not set

Public University Hospital No. 1 in Lublin, Lublin, Not set

Hospital Universitario Vall d'Hebron, Barcelona, Not set

Institut Català d'Oncologia - Hospital Duran i Reynals, Barcelona, Not set

Hospital Universitario Ramón y Cajal, Madrid, Not set

Universitätsspital Basel, Basel, Not set

Leeds Teaching Hospitals NHS Trust, Leeds, Not set

University College London Hospital - NHS Foundation Trust, London, Not set

Guy's Hospital - NHS Foundation Trust, London, Not set

Conditions: Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL), Aggressive Systemic Mastocytosis (ASM)

Learn More ›

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma

NCT05255601

Recruiting

The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.

Gender:

ALL

Ages:

30 years and below

Trial Updated:

05/28/2025

Locations: Local Institution - 0077, Birmingham, Alabama +75 locations

Local Institution - 0077, Birmingham, Alabama

Phoenix Childrens Hospital PCH - Phoenix Childrens Medical Group - Hematology Oncology, Phoenix, Arizona

Lucile Packard Childrens Hospital - Stanford University, Palo Alto, California

Yale University, New Haven, Connecticut

Local Institution - 0061, Wilmington, Delaware

Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida

Local Institution - 0017, Orlando, Florida

St. Mary's Medical Center, West Palm Beach, Florida

The Johns Hopkins Hospital JHH, Baltimore, Maryland

University of Minnesota Medical School - Masonic Childrens Hospital, Minneapolis, Minnesota

University of Mississippi Medical Center, Jackson, Mississippi

Local Institution - 0012, Saint Louis, Missouri

Hackensack University Medical Center HUMC - The Joseph M. Sanzari Childrens Hospital - Children's Cancer Institute, Hackensack, New Jersey

Local Institution - 0016, Bronx, New York

Columbia University Medical Center, New York, New York

New York Medical College, Valhalla, New York

Local Institution - 0019, Hershey, Pennsylvania

Local Institution - 0014, Nashville, Tennessee

Local Institution - 0029, Austin, Texas

CHRISTUS Childrens, San Antonio, Texas

Local Institution - 0076, Norfolk, Virginia

UW Health - American Family Children's Hospital Pediatric Bone Marrow Transplant Clinic, Madison, Wisconsin

University of New South Wales UNSW - Sydney Childrens Hospital SCH - The Centre for Cancer and Blood Disorders, Randwick, New South Wales

Royal Childrens Hospital RCH - Queensland Childrens Hospital, South Brisbane, Queensland

Perth Childrens Hospital, Nedlands, Western Australia

CHU dAngers - Pole Pediatrie, Angers, Angers Cedex 9

Groupe Hospitalier Pellegrin - Hopital des enfants, Bordeaux, Not set

Local Institution - 0033, Caen, Not set

CHU Grenoble Alpes - Hopital Couple Enfant (HCE), La Tronche, Not set

Institut d Hematologie et d Oncologie Pediatriques, Lyon, Not set

Local Institution - 0034, Marseille, Not set

Centre Hospitalier Universitaire de Montpellier CHU Montpellier - Hopital Arnaud de Villeneuve, Montpellier, Not set

Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Armand-Trousseau, Paris, Not set

Assistance Publique-Hopitaux de Paris AP-HP - Hopital Universitaire Robert-Debre, Paris, Not set

Local Institution - 0022, Rennes, Not set

CHRU de Strasbourg-Hopital de Hautepierre, Strasbourg, Not set

Local Institution - 0056, Aachen, Not set

Local Institution - 0015, Berlin, Not set

Local Institution - 0028, Giessen, Not set

Local Institution - 0036, Hamburg, Not set

Local Institution - 0008, Muenster, Not set

Local Institution - 0051, Munich, Not set

Local Institution - 0010, Aviano, Not set

Azienda Ospedaliero Universitaria di Bologna, Bologna, Not set

Azienda Ospedaliero Universitaria Meyer, Florence, Not set

Local Institution - 0005, Genoa, Not set

Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Not set

Local Institution - 0070, Milan, Not set

Fondazione MBBM - Clinica Pediatrica, Monza, Not set

Local Institution - 0013, Napoli, Not set

Azienda Ospedale Universita Padova, Padova, Not set

Local Institution - 0041, Pavia, Not set

Osp. Pediatrico Bambino Gesu; IRCCS, Roma, Not set

A.O.U. Citta della Salute e della Scienza di Torino Ospedale Infantile Regina Margherita, Turin, Not set

Princess Maxima Center for pediatric oncology, Utrecht, Not set

Hospital Sant Juan de Deu Barcelona, Esplugues de Llobregat, Barcelona

Clinica Universidad de Navarra, Pamplona, Navarra

Hospital Universitari Vall dHebron, Barcelona, Not set

Local Institution - 0009, Barcelona, Not set

Hospital Infantil Universitario Nino Jesus, Madrid, Not set

Clinica Universidad de Navarra, Madrid, Not set

Local Institution - 0044, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Universitario La Paz, Madrid, Not set

Local Institution - 0011, Santander, Not set

Local Institution - 0038, Sevilla, Not set

Hospital Universitario Virgen del Rocio HUVR, Sevilla, Not set

Hospital Universitari i Politecnic La Fe, Valencia, Not set

Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire

Alder Hey Children's NHS Foundation Trust, Liverpool, England

UCLH, London, Londonderry

Local Institution - 0003, Nottingham, Nottinghamshire

Local Institution - 0050, Bristol, Somerset

The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, Tyne And Wear

Local Institution - 0031, Birmingham, West Midlands

The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital (RMH) - Sutton, London, Not set

Conditions: Lymphoma, Non-Hodgkin, Hodgkin Disease

Learn More ›

Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure

NCT05598333

Recruiting

This is a Phase 2 adaptive, double-blinded, placebo-controlled, randomized, multi-center trial study to evaluate the safety and efficacy of a single dose of AB-1002, administered via antegrade intracoronary artery infusion, in males and females age \>18 years with non-ischemic cardiomyopathy and NYHA Class III symptoms of HF. Subjects will be randomized into one of three treatment groups in a 1:1:1

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/28/2025

Locations: Cardiology P.C. Birmingham, Birmingham, Alabama +45 locations

Cardiology P.C. Birmingham, Birmingham, Alabama

University of California San Diego, La Jolla, California

Baycare Medical Group, Clearwater, Florida

University of Miami, Coral Gables, Florida

University of Florida, Gainesville, Florida

Augusta University, Augusta, Georgia

Loyola Medicine Burr Ridge, Oakbrook Terrace, Illinois

University of Iowa, Iowa City, Iowa

University of Kansas Medical Center (KUMC), Kansas City, Kansas

Minneapolis Heart Institute Foundation, Minneapolis, Minnesota

Mayo Clinic - Minnesota, Rochester, Minnesota

St. Louis University, St. Louis, Missouri

Renown Health, Reno, Nevada

Mt. Sinai New York, New York, New York

Stony Brook, Stony Brook, New York

Sanger Heart and Vascular Institute, Charlotte, North Carolina

The Christ Hospital / The Linder Center for Research, Cincinnati, Ohio

University of Cincinnati, Cincinnati, Ohio

The Ohio State University, Columbus, Ohio

LVH Cardiology, Allentown, Pennsylvania

Medical University of South Carolina (MUSC) Medical Center, Charleston, South Carolina

Stern Cardiovascular, Germantown, Tennessee

Baylor Scott & White Advanced Heart Failure Clinic - Dallas, Dallas, Texas

Baylor College of Medicine (BCM) - Baylor Heart Clinic, Houston, Texas

Houston Methodist Debakey Cardiology Associates, Houston, Texas

University of Washington, Seattle, Washington

University of Wisconsin, Madison, Wisconsin

Medizinische Universität Graz, Graz, Not set

Kardiologie & Intensivmedizin Campus III, Linz, Not set

SALK University Hospital, Salzburg, Not set

NÖ Landesgesundheitsagentur, St.Pölten, Not set

Charité Universitaetsmedizin, Berlin, Not set

Medizinische Hochschule Hannover (MHH), Hannover, Not set

Universitätsklinikum Schleswig-Holstein, Kiel, Not set

Amsterdam UMC - Locatie AMC (Academisch Medisch Centrum), Amsterdam, North Holland

Radboud University Medical Center, Nijmegen, Not set

Erasmus Medisch Centrum, Rotterdam, Not set

Universitair Medisch Centrum (UMC) Utrecht, Utrecht, Not set

Hospital Universitario de Bellvitge, Barcelona, Catalogna

Universidad de Navarra - Clinica Universidad de Navarra (CUN), Pamplona, Navarra

Hospital Ramon y Cajal | Cardiology - Research Unit, Madrid, Not set

Universidad Autonoma de Madrid (UAM) - Hospital Universitario La Paz (HULP), Madrid, Not set

Complejo Hospitalario Universitario Santiago de Compostela (CHUS), Santiago De Compostela, Not set

Hospital Clinico Universitario de Valencia (CHUV), Valencia, Not set

Imperial College London - National Heart & Lung Institute (NHLI) - Royal Brompton Campus, London, Not set

Manchester Royal Infirmary, Manchester, Not set

Conditions: Congestive Heart Failure

Learn More ›

The Effects of a Novel Mitochondrial Substrate Supplement on Exercise Performance and Cognitive Function

NCT06374641

Recruiting

The goal of this clinical trial is to compare the effects of taking a new supplement for 16 days on cognitive function and exercise performance, compared to a placebo (a supplement that looks and tastes the same, but doesn't have the same ingredients) in 40 healthy individuals - 20 young individuals (aged 18-30) and 20 older individuals (aged 50-65). The main questions it aims to answer are: * If taking the supplement for 16 days improves exercise performance, or the speed with which the body... Read More

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

05/28/2025

Locations: Richards Building St. Lukes Campus University of Exeter, Exeter, Devon

Conditions: Exercise Performance, Cognitive Function

Learn More ›

A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

NCT06227910

Recruiting

The main aim of this study is to learn whether vedolizumab and upadacitinib given together (also called dual targeted therapy or DTT) reduces bowel inflammation and ulcers in the bowel compared to vedolizumab only (also called monotherapy) in adults with moderately or severely active Crohn's Disease (CD) after 12 weeks of treatment. Other aims are to learn how safe and effective DTT is compared to monotherapy for these participants. All participants will receive DTT (either vedolizumab and upad... Read More

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

05/28/2025

Locations: UCSD Medical Center, La Jolla, California +137 locations

UCSD Medical Center, La Jolla, California

Keck Medicine Of USC - USC Healthcare Center 1, Los Angeles, California

Peak Gastroenterology Associates, Colorado Springs, Colorado

GI PROS, Inc., Naples, Florida

Orlando Health Ambulatory Care Center, Orlando, Florida

USF Health Morsani Center for Advanced Healthcare, Tampa, Florida

Indiana University (IU) Health University Hospital, Indianapolis, Indiana

University of Kentucky, Lexington, Kentucky

Mount Sinai Hospital - The Susan and Leonard Feinstein Inflammatory Bowel Disease (IBD) Clinical Center, New York, New York

Columbia University Medical Center, New York-Presbyterian Hospital, New York, New York

Lenox Hill Hospital Northwell Health, New York, New York

Gastroenterology Associates, Greenville, South Carolina

Rapid City Medical Center, Rapid City, South Dakota

Southern Star Research Institute, LLC, San Antonio, Texas

Tyler Research Institute, LLC, Tyler, Texas

Virginia Mason Medical Center, Seattle, Washington

Swedish Cancer Institute, Seattle, Washington

University of Washington Medical Center - Montlake, Seattle, Washington

Medical College of Wisconsin Cancer Center - Froedtert Hospital, Milwaukee, Wisconsin

Medical University Innsbruck, Innsbruck, Tyrol

Medizinische Universitaet Wien - Allgemeines Krankenhaus der Stadt Wien (AKH) - Universitaetsklinik fuer Innere Medizin III, Wien, Vienna

Johannes Kepler Universitat Linz (JKU), Linz, Not set

Landeskrankenhaus Salzburg, Innere Medizin I, Labor im Erdgeschoss, Salzburg, Not set

Krankenhaus der Barmherzigen Brueder Wien, Wien, Not set

Hopital Universitaire de Bruxelles/ Academisch Ziekenhuis Brussel, Brussel, Anderlecht

Imelda GI Clinical Research Center, Bonheiden, Not set

Universitair Ziekenhuis Gent, Gent, Not set

University Hospitals Leuven, Leuven, Not set

Centre Hospitalier Chretien MontLegia, Liege, Not set

Hospital Universitario Cajuru, Curitiba, Parana

Faculdade de Medicina de Botucatu, Botucatu, Sao Paulo

Centro de Estudos Clinico do Interior Paulista - CECIP, Jau, Sao Paulo

Pesquisare Saude, Santo Andre, Sao Paulo

Universidade Federal do Rio de Janeiro (UFRJ)-Hospital Universitario Clementino Fraga Filho (HUCFF), Rio De Janeiro, Not set

Hospital das Clinicas of the University of Sao Paulo (Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (HC/FMUSP)), Sao Paulo, Not set

Unidade de Pesquisa Clinica UPC Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto da Universidade de Sao Paulo, Sao Paulo, Not set

Heritage Medical Research Clinic - University Of Calgary, Calgary, Alberta

University of Manitoba-Winnipeg Regional Health Authority-Health Sciences Centre, Winnipeg, Manitoba

Dalhousie University, Halifax, Nova Scotia

Barrie GI Associates, Barrie, Ontario

McMaster University - Farncombe Family Digestive Health Research Institute (FFDHRI), Hamilton, Ontario

Taunton Surgical Centre-Oshawa Clinic, Oshawa, Ontario

Toronto Immune and Digestive Health Institute (TIDHI), Toronto, Ontario

Toronto Digestive Disease Associates, Vaughan, Ontario

Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec

Poliklinika Borzan d.o.o., Osijek, Not set

Clinical Hospital Center Rijeka, Rijeka, Not set

University Hospital Centre Sestre Milosrdnice, Zagreb, Not set

Nemocnice Ceske Budejovice, a.s., Ceske Budejovice, Not set

Fakultni Nemocnice Hradec Kralove, Hradec Kralove, Not set

Hepato-Gastroenterologie HK, s.r.o., Hradec Kralove, Not set

IBD Clinical and Research centre, Prague, Not set

Aalborg Hospital, Aalborg, Not set

Hvidovre Hospital Medicinsk Gastroenterologisk Afdeling, Hvidovre, Not set

CHU d'Amiens-Picardie - Hopital SUD, Amiens Cedex 01, Not set

Hopital Huriez - CHRU de Lille, Lille Cedex, Not set

Chu - Hopital Nord, Marseille Cedex 20, Not set

Centre Hospitalier Universitaire de Nantes (CHU de Nantes) - Hopital Hotel Dieu, Nantes, Not set

Centre Hospitalier Universitaire de Bordeaux - Hopital Haut-Leveque, Pessac, Not set

CHU St Etienne Hopital Nord, Saint Etienne, Not set

Centre Hospitalier Universitaire (CHU) de Toulouse - Hopital Rangueil, Toulouse cedex 09, Not set

Centre Hospitalier Regional Universitaire de Nancy, Hopital Brabois, Vandoeuvre les Nancy, Not set

Krankenhaus Waldfriede e.V., Berlin, Not set

Agaplesion Markus Krankenhaus, Frankfurt Am Main, Not set

Studiengesellschaft BSF, Halle, Not set

Universitaetsklinikum Jena, Jena, Not set

Universitaetsklinikum Schleswig-Holstein, UKSH-Campus Kiel, Kiel, Not set

St. Marien- und St. Annastiftskrankenhaus, Ludwigshafen, Not set

Universitaetsklinikum Mannheim (Umm) - Ii Medizinische Klinik, Mannheim, Not set

University of Athens School of Medicine, Alexandra General Hospital, Athens, Attiki

Metaxa Cancer Hospital, Piraeus, Attiki

University Hospital of Heraklion, Heraklion, Crete

Central Hospital of Northern Pest - Military Hospital, Budapest, Not set

Semmelweis Egyetem, Budapest, Not set

Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar Szent-Gyorgyi Albert Klinikai Kozpont, I.Sz. Belogyaszati Klinika, Szeged, Not set

Adelaide, Meath and National Children's Hospital, Dublin, Not set

University College Dublin (UCD) - St. Vincent's University Hospital (SVUH), Dublin, Not set

Beaumont Hospital, Dublin, Not set

Soroka Medical Center, Be'er Sheva, Not set

Rambam Health Care Campus (RHCC), Haifa, Not set

Meir Medical Center, Kfar-Saba, Not set

Rabin Medical Center - Beilinson Campus (Beilinson and Hasharon Hospital), Petach Tikva, Not set

The Tel Aviv Sourasky Medical Center, Tel-Aviv, Not set

Ospedale San Raffaele (HSR) Instituto Scientifico Universitario San Raffaele, Milano, Not set

Azienda Ospedaliero Universitaria Federico II di Napoli, Naples, Not set

A. Gemelli University Hospital, Catholic University of the Sacred Heart, Roma, Not set

Humanitas Clinical And Research Institute, Rozzano, Not set

Fondazione IRCSS Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Not set

AO Ordine Mauriziano di Torino, Torino, Not set

Inje University Haeundae Paik Hospital, Busan, Not set

Yeungnam University Medical Center, Daegu, Not set

The Catholic University of Korea, Daejeon St.Mary's Hospital, Daejeon, Not set

Kyung Hee University Hospital, Seoul, Not set

Severance Hospital, Yonsei University Health System, Seoul, Not set

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Not set

Chung-Ang University Hospital, Seoul, Not set

The Catholic University Of Korea, St. Vincent's Hospital, Suwon-si, Not set

Amsterdam UMC Research BV, Amsterdam, Not set

Radboud University Medical Center, Nijmegen, Not set

Erasmus Medisch Centrum, Rotterdam, Not set

Elisabeth TweeSteden Ziekenhuis (ETZ), Tilburg, Not set

Vestre Viken HF - Baerum Sykehus, Drammen, Gjettum

Haukeland Universitetssjukehus (Haukeland University Hospital), Bergen, Not set

Akershus University Hospital, Lorenskog, Not set

Oslo Universitetssykehus HF, Ulleval, Oslo, Not set

Oddzial Kliniczny Gastroenterologii Ogolnej i Onkologicznej SPZOZ Uniwersytecki Szpital Kliniczny Nr 1 im. Barlickiego Uniwersytetu Medycznego w Lodzi, Lodz, Not set

Samodzielny Publiczny Szpital Kliniczny Im. H. Swiecickiego Um, Poznan, Not set

H-T. Centrum Medyczne Sp. z o.o. Sp.k., Tychy, Not set

WIP Warsaw IBD Point Profesor Kierkus, Warsaw, Not set

Panstwowy Instytut Medyczny MSWiA, Warszawa, Not set

Unidade Local de Saude Coimbra, Coimbra, Not set

Centro Hospitalar Universitario Lisboa Norte EPE, Lisboa, Not set

Centro Hospitalar de Lisboa ocidental (CHLO), Hospital Egas Moniz, Lisbon, Not set

University Clinical Centre - Ljubljana, Ljubljana, Not set

Hospital General Universitario Gregorio Maranon (HGUGM), Madrid, Not set

Hospital Universitario La Paz, Madrid, Not set

Hospital Universitari Son Espases, Palma, Not set

Complejo Hospitalario de Navarra (CHN), Pamplona, Not set

Complejo Hospitalario Universitario De Santiago De Compostela, Santiago de Compostela, Not set

Hospital Universitari I Politecnic La Fe, Valencia, Not set

Universitetssjukhuset i Linkoping, Endokrin- och magtarmmedicinska Kliniken (EM-Kliniken), Linkoping, Not set

Ersta sjukhus, Stockholm, Not set

Karolinska Universitetssjukhuset - Hjartkliniken i Solna - Karolinska University Hospital, Stockholm, Not set

Danderyds Sjukhus AB, Stockholm, Not set

University Hospital Basel, Basel, Not set

University Hospital Bern (Inselspital), Bern, Not set

Zentrum fur Gastroenterologie, Zurich, Not set

Universitatsspital Zurich, Zurich, Not set

Changhua Christian Hospital, Changhua City, Not set

Chung Shan Medical University Hospital, Taichung, Not set

Taichung Veterans General Hospital, Taichung, Not set

National Cheng Kung University Hospital, Tainan, Not set

National Defense Medical Center (NDMC) (Tri-Service General Hospital (TSGH)) - Neihu, Taipei, Not set

Chang Gung Memorial Foundation Linkou Chang Gung Memorial Hospital, Taoyuan City, Not set

St Thomas' Hospital - Guy's & St Thomas' NHS Foundation Trust, London, England

The Royal London Hospital - Barts Health NHS Trust, London, Greater London

Western General Hospital, Edinburgh, Lothian

Queen Elizabeth University Hospital - NHS Greater Glasgow & Clyde - South Glasgow University Hospital Division, Glasgow, Scotland

Conditions: Crohn's Disease

Learn More ›